P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort | Zendy

AI Assistant Blog Pricing

P592 Final results on immunogenicity profile and predictors of ADA development of biosimilar infliximab during the first 12 months of the therapy: results from a prospective nationwide cohort

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.